Purpose: We aimed to assess the characteristics of inflammatory rheumatic disease (IRD) patients in Kuwait diagnosed with COVID-19 and the factors linked with hospitalization, complications, and mortality.
Methods: Data of IRD patients from Kuwait diagnosed with COVID-19 between March 2020 and March 2021, submitted to the COVID-19 Global Rheumatology Alliance physician-reported registry, were included in our analysis. Data on patients' age, gender, smoking, diagnosis, IRD activity, and other comorbidities were collected. Statistical Package for the Social Sciences (SPSS), version 25, was used for statistical analysis.
Results: A total of 52 patients were included, with a mean age of 55 years (±14). The majority of patients were ≤65 years (77%), female (77%), non-smokers (80.8%), and diagnosed with rheumatoid arthritis (67.0%). Of the included patients, 19.2%, 9.6%, and 7.7% reported having methotrexate monotherapy, antimalarials monotherapy, and interleukin-6 inhibitors monotherapy immediately before COVID-19, respectively. Most of the included patients (92.3%) were either in remission or had minimal/low disease activity, while others (7.7%) had moderate disease activity. Forty-three patients (82.7%) were hospitalized, while 11 patients (25.6%) required ventilation (invasive or non-invasive). Ten of the ventilated patients (90.9%) received glucocorticoids as part of the local protocol to treat severe COVID symptoms, and 4 patients (7.69%) died. The duration till symptom-free ranged between 0 to 30 days, with a mean value of 10 days (±6.5).
Conclusion: The current study provides timely real-world evidence regarding characteristics and potential risk factors linked to poor COVID-19-related outcomes in the IRD population in Kuwait.
Keywords: COVID-19; Global Rheumatology Alliance; Kuwait; anti-rheumatic drugs; rheumatic disease.
Baron F, Alhajeri H, Abutiban F, Almutairi M, Alawadhi A, Aldei A, Alherz A, Ali Y, Alsayegh S, Dehrab A, Ghanem A, Hajji E, Hayat S, Saleh K, Shaikh-Alsooq R, Tarakmah H, Albasri A, Alenezi A, Alhadhood N, Alkanderi W, Almathkoori A, Almutairi N, Alturki A, Alkadi A, Behbahani H.Curr Rheumatol Rev. 2022;18(2):108-116. doi: 10.2174/1573397117666211007091256.PMID: 34620059 Review.
